Is HRMY a good stock to buy?
We came across a bullish thesis on Harmony Biosciences Holdings, Inc. on r/StockPickNews by EaseQuiet529
In this article, we will summarize the bulls’ thesis on HRMY. Harmony Biosciences Holdings, Inc.’s share was trading at $34.10 as of June 9th. HRMY’s trailing and forward P/E were 13.75 and 10.81 respectively according to Yahoo Finance.
Pressmaster/ Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. HRMY is emerging as a compelling opportunity in the biopharma space following a period of market underappreciation, with its current valuation failing to reflect the strength of its core asset and growth pipeline. 15 AI Stocks That Are Quietly Making Investors Rich Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential Trading around $27.70–$27.80 with a modest market capitalization of approximately $1.6 billion, the stock appears significantly discounted relative to its fundamentals, as evidenced by a low trailing P/E of ~7.8x and forward P/E of ~11.4x, alongside a PEG ratio of just 0.38. The company’s flagship drug, WAKIX, remains the cornerstone of its investment thesis, with management reaffirming 2026 revenue guidance of $1.0 billion to $1.04 billion, positioning the drug to achieve blockbuster status.